Investigational Drug Information for Tezosentan
✉ Email this page to a colleague
What is the development status for investigational drug Tezosentan?
Tezosentan is an investigational drug.
There have been 6 clinical trials for Tezosentan.
The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2003.
The most common disease conditions in clinical trials are Hypertension, Pulmonary Arterial Hypertension, and Familial Primary Pulmonary Hypertension. The leading clinical trial sponsors are Actelion, Idorsia Pharmaceuticals Ltd., and Medical University of Vienna.
Summary for Tezosentan
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,100 |
| WIPO Patent Applications | 625 |
| Japanese Patent Applications | 7 |
| Clinical Trial Progress | Phase 3 (2003-04-01) |
| Vendors | 44 |
Recent Clinical Trials for Tezosentan
| Title | Sponsor | Phase |
|---|---|---|
| Tezosentan in Patients With Pulmonary Arterial Hypertension | Actelion | Phase 2 |
| Tezosentan in Patients With Pulmonary Arterial Hypertension | Idorsia Pharmaceuticals Ltd. | Phase 2 |
| Tezosentan in Pulmonary Arterial Hypertension | Actelion | Phase 2 |
Clinical Trial Summary for Tezosentan
Top disease conditions for Tezosentan
Top clinical trial sponsors for Tezosentan
US Patents for Tezosentan
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
